guidanc cut lower pt
mix result anoth guidanc cut reduc
revenu ep estim cut primarili reflect weaker
expect sale g-androgel continu sluggish perform
rx pharma divis also lower ep estim
await addit commentari new ceo plan turnaround
plan upcom investor meet next spring
new ep estim align manag lower
guidanc primarili reflect lower contribut g-androgel due aggress
competit author gener weak gener busi
project revenu ep line guidanc
previous manag refrain provid financi guidanc
also reduc revenu ep estim
lower price roll forward valuat metric approach
new price target vs base price-to-earnings multipl vs
due uneven execut late updat ep estim
financi restat reflect divestitur tysabri
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
page
pleas see import disclosur inform page report
manag guidancetot op op sale contribut rx product net net oper adj op profit estim
chart perrigo incom statement except per-shar data
risk invest case includ gener price eros delay new product launch sluggish chca chci growth
page
pleas see import disclosur inform page report
fy gross oper sg total oper oper net interest/oth pre-tax net share outstand share outstand report ep ep restat reflect tysabri divestitur held sale busi us vm eu sport brand india api
perrigo compani plc lead global healthcar supplier develop manufactur distribut over-the-count over-the-counter
prescript rx pharmaceut nutrit product activ pharmaceut ingredi api
price target base forward price-to-earnings multipl support dcf analysi risk includ gener price eros delay
new product launch sluggish chca chci growth
david steinberg certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
edward chung certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
anthoni baldor certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
case jefferi employe analyst respons coverag financi instrument discuss report receiv
compens base part overal perform firm includ invest bank incom seek updat research
appropri variou regul may prevent us asid certain industri report publish period basi larg major
report publish irregular interv appropri analyst judgement
articl articl
explan jefferi rate
buy describ secur expect provid total return price appreci plu yield within period
hold describ secur expect provid total return price appreci plu yield plu minu within period
under-perform describ secur expect provid total return price appreci plu yield minu less within
expect total return price appreci plu yield buy rate secur averag secur price consist
within period compani typic volatil overal stock market hold rate secur averag
secur price consist expect total return price appreci plu yield plu minu within period
under-perform rate secur averag secur price consist expect total return price appreci plu yield minu
less within period
nr invest rate price target temporarili suspend suspens complianc applic regul and/
jefferi polici
cs coverag suspend jefferi suspend coverag compani
nc cover jefferi cover compani
restrict describ issuer conjunct jefferi engag certain transact compani polici applic secur regul
prohibit certain type commun includ invest recommend
monitor describ secur whose compani fundament financi monitor financi project opinion
invest merit compani provid
jefferi methodolog assign rate may includ follow market capit matur growth/valu volatil expect total
return next month price target base sever methodolog may includ restrict analys market
premium discount /averag group ev/ebitda premium discount /averag group price-to-earnings sum part net asset valu dividend return
return equiti roe next month
page
pleas see import disclosur inform page report
